137 related articles for article (PubMed ID: 37300383)
1. Dual immunocytochemical staining of annexin A10 and p53 in low-grade and papillary urothelial carcinoma contributes to improvement of diagnostic accuracy in urine cytology.
Kobayashi G; Hayashi T; Sentani K; Uraoka N; Shibata J; Nobuhiro R; Saito Y; Ishida K; Kaneko Y; Ikeda K; Hanamoto M; Nose H; Arihiro K; Hinata N; Oue N
Cancer Cytopathol; 2023 Sep; 131(9):548-560. PubMed ID: 37300383
[TBL] [Abstract][Full Text] [Related]
2. ANXA10 Expression Is Inversely Associated with Tumor Stage, Grade, and TP53 Expression in Upper and Lower Urothelial Carcinoma.
Kobayashi G; Hayashi T; Sentani K; Ikeda K; Babasaki T; Shigematsu Y; Sekino Y; Uraoka N; Teishima J; Matsubara A; Hinata N; Oue N
Pathobiology; 2023; 90(2):94-103. PubMed ID: 35780773
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic significance of dual immunocytochemical staining of p53/cytokeratin20 on liquid-based urine cytology to detect urothelial carcinoma.
Choi SY; Kim KH; Suh KS; Yeo MK
Cytojournal; 2020; 17():3. PubMed ID: 32256669
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic value of a comprehensive, urothelial carcinoma-specific next-generation sequencing panel in urine cytology and bladder tumor specimens.
Sun T; Hutchinson L; Tomaszewicz K; Caporelli ML; Meng X; McCauley K; Fischer AH; Cosar EF; Cornejo KM
Cancer Cytopathol; 2021 Jul; 129(7):537-547. PubMed ID: 33539671
[TBL] [Abstract][Full Text] [Related]
5. Immunocytochemical staining for p53 and Ki-67 helps to characterise urothelial cells in urine cytology.
Courtade-Saïdi M; Aziza J; d'Aure D; Bérard E; Evrard S; Basset C; Lacoste-Collin L
Cytopathology; 2016 Dec; 27(6):456-464. PubMed ID: 27873391
[TBL] [Abstract][Full Text] [Related]
6. Upper tract urinary cytology to detect upper tract urothelial carcinoma: Using the Johns Hopkins Hospital template and evaluation of its feasibility.
Chen L; He H; Zarka MA; Zhou M; Magi-Galluzzi C
Cytojournal; 2015; 12():17. PubMed ID: 26288652
[TBL] [Abstract][Full Text] [Related]
7. MCM4 expression is associated with high-grade histology, tumor progression and poor prognosis in urothelial carcinoma.
Kobayashi G; Hayashi T; Sentani K; Uraoka N; Fukui T; Kido A; Katsuya N; Ishikawa A; Babasaki T; Sekino Y; Nose H; Arihiro K; Hinata N; Oue N
Diagn Pathol; 2023 Sep; 18(1):106. PubMed ID: 37737200
[TBL] [Abstract][Full Text] [Related]
8. Diagnosis of urinary bladder urothelial carcinoma by immunocytology with p53, MCM5, MCM2 and Ki-67 antibodies using cell blocks derived from urine.
Brisuda A; Háček J; Čechová M; Škapa P; Babjuk M
Cytopathology; 2019 Sep; 30(5):510-518. PubMed ID: 30943322
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathological significance of TUBB3 in upper tract urothelial carcinoma and possible application in urine cytology.
Kobayashi G; Hayashi T; Sentani K; Uraoka N; Fukui T; Kido A; Katsuya N; Ishikawa A; Babasaki T; Sekino Y; Nose H; Hinata N; Oue N
Pathol Int; 2023 Sep; 73(9):444-455. PubMed ID: 37589430
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathological significance of the overexpression of MUC1 in upper tract urothelial carcinoma and possible application as a diagnostic marker.
Kobayashi G; Hayashi T; Sentani K; Takemoto K; Sekino Y; Uraoka N; Hanamoto M; Nose H; Teishima J; Arihiro K; Hinata N; Oue N
Pathol Int; 2022 Dec; 72(12):606-616. PubMed ID: 36169278
[TBL] [Abstract][Full Text] [Related]
11. Mixed low- and high-grade papillary urothelial carcinoma: histopathogenetic and clinical significance.
Mai KT; Flood TA; Williams P; Kos Z; Belanger EC
Virchows Arch; 2013 Oct; 463(4):575-81. PubMed ID: 23913166
[TBL] [Abstract][Full Text] [Related]
12. Is Diagnosis of Low-Grade Urothelial Carcinoma Possible in Urine Cytology?
Bansal S; Pathuthara S; Joseph S; Dighe S; Menon S; Desai SB
J Cytol; 2021; 38(2):64-68. PubMed ID: 34321771
[TBL] [Abstract][Full Text] [Related]
13. An institutional experience with The Paris System: A paradigm shift from ambiguous terminology to more objective criteria for reporting urine cytology.
Roy M; Kaushal S; Jain D; Seth A; Iyer VK; Mathur SR
Cytopathology; 2017 Dec; 28(6):509-515. PubMed ID: 28833848
[TBL] [Abstract][Full Text] [Related]
14. Atypical Category of the Johns Hopkins Template Has Higher Risk of Malignancy than the Paris System but the Paris System Is More Applicable for Suspicious Category.
Celik B; Kavas G
Acta Cytol; 2023; 67(4):425-433. PubMed ID: 36731438
[TBL] [Abstract][Full Text] [Related]
15. Detection of pagetoid urothelial intraepithelial neoplasia extending to the vagina by cervical screening cytology: a case report with renewed immunochemical summary.
Koyanagi Y; Kubo C; Nagata S; Ryu A; Hatano K; Kano R; Tanada S; Ashimura JI; Idota A; Kamiura S; Yamasaki T; Nakatsuka SI
Diagn Pathol; 2019 Feb; 14(1):9. PubMed ID: 30711015
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic Significance of Cytokeratin 20 and p53 as Adjunct Immunocytological Markers in Urine Cytology to Detect Urothelial Carcinomas: A Systematic Review Study.
Angel E
Iran J Pathol; 2023; 18(3):257-269. PubMed ID: 37942190
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic Immunocytostaining with Peroxisome Proliferator-Activated Receptor-Gamma in Urine Cytology Samples.
Tanaka S; Tokuhara Y; Ariyasu S; Morinishi T; Yamamoto T; Teramoto N; Hirakawa E
Acta Cytol; 2024; 68(1):60-65. PubMed ID: 38008063
[TBL] [Abstract][Full Text] [Related]
18. ROS generation via NOX4 and its utility in the cytological diagnosis of urothelial carcinoma of the urinary bladder.
Shimada K; Fujii T; Anai S; Fujimoto K; Konishi N
BMC Urol; 2011 Oct; 11():22. PubMed ID: 22032647
[TBL] [Abstract][Full Text] [Related]
19. The use of urinary nuclear matrix protein 22 (NMP22) as a diagnostic adjunct to urine cytology for monitoring of recurrent bladder cancer--institutional experience and review.
Önal B; Han Ü; Yilmaz S; Köybasioglu F; Altuğ U
Diagn Cytopathol; 2015 Apr; 43(4):307-14. PubMed ID: 25488052
[TBL] [Abstract][Full Text] [Related]
20. The Paris System for reporting urinary cytology improves the negative predictive value of high-grade urothelial carcinoma.
Yamasaki M; Taoka R; Katakura K; Matsunaga T; Kani N; Honda T; Harada S; Tohi Y; Matsuoka Y; Kato T; Okazoe H; Tsunemori H; Ueda N; Haba R; Sugimoto M
BMC Urol; 2022 Apr; 22(1):51. PubMed ID: 35382830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
